• If you are wondering whether Thermo Fisher Scientific stock is priced attractively today, the key clues sit in how its current market value compares with its fundamentals.
• The stock last closed at US$513.03, with recent price moves including a 10.4% return over the past week, 12.5% over the past month, a decline of 13.4% year to date, and a 26.1% return over the last year.
• These mixed returns across different time frames can reflect shifting expectations about Thermo Fisher Scientific and how investors interpret recent developments. Without anchoring on any single headline, it is helpful to view the stock's moves against the broader context of company specific news and ongoing market sentiment.
• Thermo Fisher Scientific currently has a valuation score of 3 out of 6, which means it screens as undervalued on half of the checks used here. The rest of this article will unpack those valuation methods and will also point to an even more complete way of thinking about value at the end.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Thermo Fisher Scientific stock could be worth by projecting future cash flows and then discounting them back to today using a required return. It is essentially asking what all of those future dollars are worth in today’s terms.

Thermo Fisher Scientific has last twelve month Free Cash Flow of about $6.79b. Based on analyst inputs and extrapolations, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, with projected Free Cash Flow of $11.45b in 2030. The 10 year path between these figures is built from a mix of analyst estimates out to 2029 and then mechanically extended beyond that.

Adding up those discounted cash flows produces an estimated intrinsic value of $578.76 per share, compared with the recent market price of $513.03. That indicates the stock screens as approximately 11.4% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 11.4%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For profitable companies like Thermo Fisher Scientific, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. It links the share price directly to the bottom line, which is usually more stable than revenue or book value for established businesses.

What counts as a “normal” or “fair” P/E ratio depends on how investors view a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher uncertainty typically points to a lower one.

Thermo Fisher Scientific currently trades on a P/E of 27.84x. This sits below the Life Sciences industry average P/E of 36.21x and also below the peer group average of 42.44x. Simply Wall St’s Fair Ratio framework estimates what a more tailored P/E might look like, given factors such as Thermo Fisher Scientific’s earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it is company specific, this Fair Ratio of 25.76x can be more informative than a simple comparison with broad industry or peer averages. Set against the current P/E of 27.84x, Thermo Fisher Scientific screens as somewhat overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier the article mentioned that there is an even better way to understand valuation. On Simply Wall St this takes the form of Narratives, where you set out your story for Thermo Fisher Scientific, link that story to assumptions for future revenue, earnings and margins, and the platform then turns it into a financial forecast, a fair value and a clear comparison against today’s share price that updates automatically when fresh information arrives.

On the Community page, millions of investors already use Narratives as a simple tool to frame different viewpoints. For example, one Thermo Fisher Scientific Narrative might lean toward the lower fair value of US$490 with assumptions closer to 6.0% annual revenue growth and higher perceived risks around margins. Another might lean toward the upper fair value of about US$721 with assumptions closer to 7.4% annual revenue growth and stronger margin potential. By comparing each Narrative’s fair value to the current price you can see whether your own story suggests the stock looks expensive or inexpensive without having to build a full model from scratch.

For Thermo Fisher Scientific however we will make it really easy for you with previews of two leading Thermo Fisher Scientific Narratives:

These sit on opposite sides of the fair value range, so you can quickly see how different assumptions on growth, margins and risks translate into very different views on what the stock may be worth.

Fair value: US$720.95 per share

Gap to this fair value: about 28.8% below the narrative estimate based on the latest close

Revenue growth assumption: 7.43% a year

• Sees Thermo Fisher Scientific gaining share in areas such as AI supported tools, proteomics and bioprocessing, helped by product depth and a broad service offering.
• Assumes revenue growth of about 7.4% each year, profit margins rising into the high teens, and a 2029 P/E of 31.9x to support a fair value around US$721.
• Flags risks from tariffs, weaker academic funding, acquisition execution and possible commoditisation of some lab workflows, which could undermine this more optimistic path.

Fair value: US$490.00 per share

Gap to this fair value: about 4.7% above the narrative estimate based on the latest close

Revenue growth assumption: 5.96% a year

• Frames Thermo Fisher Scientific as more constrained by geopolitics, pricing pressure and acquisition dependence, which could hold back margins and organic growth.
• Assumes revenue growing closer to 6.0% a year, margins only slightly higher than today and a 2029 P/E of 26.0x, which together point to a fair value of US$490.
• Notes that long term demand for healthcare and research, plus ongoing investment in new tools and services, could offset some of these pressures if they play out more positively.

Both narratives use the same current share price but very different views on Thermo Fisher Scientific’s future earnings power, which is why they arrive at such different fair values. The most useful step now is to decide which assumptions look closer to how you see the business, then track how new data, quarterly results and sector news either support or challenge that story over time.

To see how these results tie into long term growth, risks and valuation, and to compare your own view with other investors, it is worth reviewing the full range of community Narratives and related valuation work for Thermo Fisher Scientific, including the detailed company report and risk breakdown. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Thermo Fisher Scientific on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.